ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2907

Comparison of the Joints Ultrasonography in the Patients with Rheumatoid Arthritis Treated By Biological Agents and the Corresponding Synovial Histological Findings

Asami Abe1, Hajime Ishikawa2 and Kunihiko Wakaki3, 1Rheumatology, Niigata Rheumatic Center, Shibata, Japan, 2Department of Rheumatology, Niigata Rheumatic Center, Shibata, Japan, 3Pathology, Niigata Prefectural Shibata Hospital, Shibata, Japan

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: Biologic agents, histopathologic, rheumatoid arthritis (RA) and ultrasonography

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Wednesday, October 24, 2018

Title: 6W006 ACR Abstract: Imaging of Rheumatic Diseases II: Ultrasound (2904–2909)

Session Type: ACR Concurrent Abstract Session

Session Time: 9:00AM-10:30AM

Comparison of the joints ultrasonography in the patients with rheumatoid arthritis treated by biological agents and the corresponding synovial histological findings

Background/Purpose: In the treatment of Rheumatoid arthritis (RA), early diagnosis and early treatment with tight control have become increasingly important with the advent of biological therapy. Ultrasonography (US) of the various joints enables the real-time evaluation of synovial hypertrophy, effusion and bone erosion, Power Doppler (PD) ultrasound is able to identify both subclinical synovitis and early erosive disease. The objectives of this study were to investigate whether the image of US at the operated joint reflect synovium histopathology or clinical indicators, and to compare the results in the patient treated by non-biological agent (NonBio) and biological agent (Bio)..

Methods: RA related orthopaedic surgery was performed at 1191 joints including 17 shoulders, 144 knees, 92 elbows, 352 wrists, 333 fingers, 34 ankles and 218 toes during the period between January 2011 and May 2018 at our rheumatic center. Preoperatively, ultrasound evaluations were performed and grade of PD signal was determined at the part with the highest signal. PD signal consists 4 grades from grade 0 to 3. The operations were performed within one week after the ultrasound evaluations.  Rooney score of the synovium pathology, DAS28-ESR(4), MMP-3, CRP were investigated. Rooney score represents the histologic features in the synovium of RA.  It includes 6 features i.e. synoviocytes hyperplasia, fibrosis, proliferating blood vessels, perivascular infiltrates of lymphocytes, focal aggregates of lymphocytes, diffuse infiltrates of lymphocytes. They were scored separately on a scale of 1-10.The treatments that the patients received included: biological agents (Bio) (n=351 29%), etanercept (ETN) (n= 96), tocilizumab (TCZ) (n=99), infliximab (IFX) (n=25), adalimumab (ADA) (n=26), certlizumab pegol (CZP) (n=8), golimumab (GLM) (n=49), and abatacept (ABT) (n=47), tofacitinib (TOF) (n=1).

Results: PD signal (0.75}0.89), DAS28 (2.77}1.13), CRP(0.10}1.22 mg/dL), MMP-3 (104.6}108.4 ng/mL) and Rooney score (22.1}7.7) in the patients treated by Bio were significantly lower than those (1.41}0.96, 3.67}1.11, 0.79}1.32 mg/dL, 145.0}138.2 ng/dL, 28.5}9.24 ) in the patients using NonBio. Rooney score fibrosis (9.57}1.51) in patients using Bio was significantly higher than those (8.55}2.45) in patients treated by NonBio. Rooney score synoviocyte hyperplasia (0.91}1.27), three items of lymphocyte (1.59}2.91, 1.38}2.49, 0.86}2.27) in patients treated Bio were lower than those (1.73}1.30, 3.84}3.56, 3.70}3.48, 2.47}2.93) in patients treated by NonBio. TCZ, ADA, ABT and IFX had some significant differences for Rooney score and Rooney item score between the patients treated NonBio.

Conclusion: The activity of RA synovitis at operated site was suppressed in patients treated by Bio. There were some differences in clinical data, histopathological score, PD signal and DAS among Bio.


Disclosure: A. Abe, None; H. Ishikawa, None; K. Wakaki, None.

To cite this abstract in AMA style:

Abe A, Ishikawa H, Wakaki K. Comparison of the Joints Ultrasonography in the Patients with Rheumatoid Arthritis Treated By Biological Agents and the Corresponding Synovial Histological Findings [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/comparison-of-the-joints-ultrasonography-in-the-patients-with-rheumatoid-arthritis-treated-by-biological-agents-and-the-corresponding-synovial-histological-findings/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/comparison-of-the-joints-ultrasonography-in-the-patients-with-rheumatoid-arthritis-treated-by-biological-agents-and-the-corresponding-synovial-histological-findings/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology